论文部分内容阅读
评价尿激酶和蝮蛇抗栓酶对急性心肌梗塞的溶栓效果，以选择有效而可靠的溶栓药物。将１００例急性心肌梗塞病人分成两组，分别用尿激酶和蝮蛇抗栓酶进行溶栓治疗。尿激酶组６０例（男４６例，女１４例），蝮蛇抗栓酶组４０例（男２２例，女１８例）。结果，尿激酶组明显优于蝮蛇抗栓酶组，蝮蛇抗栓酶对急性心肌梗塞早期疗效不佳。结果提示，尿激酶溶栓疗效肯定，蝮蛇抗栓酶不能作为急性心肌梗塞早期溶栓的首选药，但是对于入院偏晚的病人，连续应用还是能够取得一定效果的。
Evaluation of urokinase and viper antithrombolytic thrombolytic effect of acute myocardial infarction in order to select an effective and reliable thrombolytic drugs. 100 cases of acute myocardial infarction patients were divided into two groups, respectively, urokinase and viper antithrombolytic enzyme thrombolytic therapy. Urokinase group 60 cases (46 males and 14 females), viper antithrombolytic group of 40 patients (22 males and 18 females). Results, urokinase group was significantly superior to viper antithrombin group, viper snake antithrombotic efficacy of acute myocardial infarction in the early poor. The results suggest that urokinase thrombolytic therapy affirmation, viper antithrombin can not be used as early thrombolytic acute myocardial infarction drug, but for patients with late admission, continuous application or to be able to achieve some results.